Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C

Abhishek Bhatia, Alexander J. Preiss, Xuya Xiao, M. Daniel Brannock, G. Caleb Alexander, Robert F. Chew, Megan Fitzgerald, Elaine Hill, Elizabeth P. Kelly, Hemalkumar B. Mehta, Charisse Madlock-Brown, Kenneth J. Wilkins, Christopher G. Chute, Melissa Haendel, Richard Moffitt, Emily R. Pfaff, The N3C Consortium
doi: https://doi.org/10.1101/2023.05.03.23289084

Data Availability

All data is available in the N3C Data Enclave to those with an approved protocol and data use request from an institutional review board. Data access is governed under the authority of the National Institutes of Health; more information on accessing the data can be found at https://covid.cd2h.org/for-researchers. See Haendel et. al. for additional detail on how data is ingested, managed, and protected within the N3C Data Enclave.

Back to top
Posted May 04, 2023.
Download PDF
Data/Code
Email
Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
Abhishek Bhatia, Alexander J. Preiss, Xuya Xiao, M. Daniel Brannock, G. Caleb Alexander, Robert F. Chew, Megan Fitzgerald, Elaine Hill, Elizabeth P. Kelly, Hemalkumar B. Mehta, Charisse Madlock-Brown, Kenneth J. Wilkins, Christopher G. Chute, Melissa Haendel, Richard Moffitt, Emily R. Pfaff, The N3C Consortium
medRxiv 2023.05.03.23289084; doi: https://doi.org/10.1101/2023.05.03.23289084
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area